News

The data show that RGB-286638 demonstrates in vivo activity in several preclinical models of multiple myeloma. The compound also induces cell death in multiple myeloma cells independent from

Patient Safety Technologies, a developer, manufacturer and provider of patient safety products and services, has reported a net loss of $630,000, or $0.05 per share, for the fourth

Quarterly Snapshot Revenues decreased 12% Adjusted EPS declined 15% Generated record free cash flow of more than $310 million Significant new products launched to address customer needs for

Business Outlook For the fiscal 2009, the company anticipates total revenue to be in the range of $164 million to $174 million, loss per share in the range

2009 Guidance Update Looking ahead for fiscal 2009, Amgen projects revenue outlook to a range of $14.4 billion to $14.8 billion from its prior estimate of $14.8 billion

“We are very pleased to have ELITech UK become our exclusive UK distributor. Their demonstrated expertise in this market and knowledge of our customer base in the UK

Excluding a 10% currency impact, first quarter sales grew organically by 1% from a year ago. Organic sales for the Company’s Research business grew over 3%, with individual

NanoBio, a biopharmaceutical company, has reported that the FDA has approved the company’s investigational new drug application for the Phase I clinical study of NB-1008, a seasonal influenza

Pharmasset, a clinical-stage pharmaceutical company, has reported that after a discussion with its independent data safety monitoring board and the FDA, the company has decided to voluntarily terminate